United Kingdom · Question · Written question
HL HL15254
Multiple Myeloma: Drugs
Introduced
26 April 2021
Last action
29 April 2021 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
29 April 2021
Summary
To ask Her Majesty's Government when they expect to receive a report from the National Institute for Clinical Excellence on the (1) efficacy, and (2) cost effectiveness, of the daratumumab treatment for myeloma; how long that evaluation has been in progre
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
26 April 2021
Written question
To ask Her Majesty's Government when they expect to receive a report from the National Institute for Clinical Excellence on the (1) efficacy, and (2) cost effectiveness, of the daratumumab treatment for myeloma; how long that evaluation has been in progre
Source: Lords
29 April 2021
Answer
Daratumumab has been appraised by the National Institute for Health and Care Excellence (NICE) in several different indications related to different stages of multiple myeloma and in combination with other treatments. NICE has been able to recommend darat...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2021-04-26/HL15254
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1311973
- uk · wq-1311973 · source updated 29 April 2021